All In Biotech

Drug Trial Radar · NCT07167914

A Study to Assess Safety, Tolerability and Pharmacokinetics of Transdermal SFG-02 in Healthy Participants

A Phase 1 Study to Assess Safety, Tolerability and Pharmacokinetics of Single and Multiple Transdermal Doses of SFG-02 in Japanese and White Healthy Adult Participants

Last checked: Nov 20, 2026Latest source record: Oct 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

32

Actual

Start

Sep 9, 2025

Primary completion

Apr 27, 2026

Study completion Apr 27, 2026

Sponsor

Lead sponsor
Juro Sciences Inc.Industry
Sponsor type
Industry
First posted
Sep 11, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This Phase 1 study will evaluate the safety, tolerability, and pharmacokinetics of a novel transdermal formulation of SFG-02 following single and repeated applications in Japanese and White healthy adult participants.

Conditions

  • Health Participants

Interventions

  • SFG-02Drug

    Transdermal Formulation (SFG-02)

  • PlaceboDrug

    Transdermal Formulation (Placebo)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and TolerabilityTime frame: From the first application to the 14th day after the final application
  2. Pharmacokinetics (PK): Maximum concentration (Cmax) of SFG-02Time frame: At designated timepoints (up to 7 days after the final application)
  3. PK: Area under the concentration versus time curve (AUC) of SFG-02Time frame: At designated timepoints (up to 7 days after the final application)
  4. PK: Time to maximum concentration (Tmax) of SFG-02Time frame: At designated timepoints (up to 7 days after the final application)
  5. PK: Time to decrease the concentration by half (T1/2) of SFG-02Time frame: At designated timepoints (up to 7 days after the final application)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Sumida Hospital

    Tokyo, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.